Phase 1 safety and efficacy of IMC-F106C, a PRAME × CD3 ImmTAC bispecific, in post-checkpoint cutaneous melanoma (CM). This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I. This ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results